PLPL Trademark DIEGO PELLICIER - das neue Starbucks für Marihuana ? - 500 Beiträge pro Seite

[guay]

Mister Jamen Shively (45), Ex-Manager beim Software-Giganten Microsoft, will Amerikas erste Marihuana-Kette gründen – eine Art „Starbucks für Gras“. Shively ist seit heute auch im Aufsichtsrat von Plandai Biotechnology. Jamen Shively ist Mitbegründer von DIEGO PELLICER eine Edelmarke für Marijuana-Produkte sh. http://diegopellicer.com
Am 07. Februar 2014 erwarb Plandai die Lizenz der Marke DIEGO PELLICER. Seit 03. Februar ist die PLPL Aktie in einem Abwärtstrend - wird dieser Trend Heute unterbrochen? Wird es jetzt, auch angefacht durch die Meldungen der letzten Tage, wieder Richtung Norden gehen?
Ihr 52 W Hoch hatte die Plandai Bio Aktie (WKN: A1JSDB) erst vor kurzem, am 03. Februar 2014, mit 3,12 US $. Wird diese Marke in den kommenden Wochen gebrochen werden? Im Moment steht die Aktie bei 1,44 US $ ... ist das ein guter Einstiegspreis?

Hier noch ein paar links zu der Meldung des heutigen Tages:

http://www.spiegel.de/video/ex-microsoft-manager-plant-canna…

http://www.bild.de/geld/wirtschaft/marihuana/ex-microsoft-ma…" target="_blank" rel="nofollow ugc noopener">http://www.bild.de/geld/wirtschaft/marihuana/ex-microsoft-ma…


http://www.sueddeutsche.de/wirtschaft/marihuana-kette-von-ex…" target="_blank" rel="nofollow ugc noopener">http://www.sueddeutsche.de/wirtschaft/marihuana-kette-von-ex…

[guay]

Wall Street Journal

http://online.wsj.com/article/PR-CO-20140213-914473.html

Plandai Biotechnology Names Diego Pellicer Co-Founder and Cannabis Pioneer Jamen Shively to Board of Directors

NEW YORK, NY--(Marketwired - Feb 13, 2014) - Plandaí Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, announced today that it has named Jamen Shively, a leading voice in the burgeoning marijuana industry and co-founder of the Diego Pellicer group of companies, to its Board of Directors. Mr. Shively will be filling the vacancy created with the resignation of David Rzepnicki, who recently resigned.

Roger Duffield, Chief Executive Officer of Plandaí, commented on the appointment of Mr. Shively to the Board, "Jamen brings a wealth of experience in both engineering and branding to Plandaí not to mention his bold leadership in the cannabis field. As a member of Plandaí's Board, Jamen will be instrumental in helping shape our corporate policy and direction as we move from being a research company into production and sales in the coming months."

Jamen Shively, age 45, has a background in engineering and marketing, with specialties in artificial intelligence, the modeling and optimization of complex networks, and the creation and positioning of new categories of products and services. Jamen co-founded Diego Pellicer Inc. in 2012, and built the brand from zero to the #1 most recognized brand of cannabis in the world in less than one year. Prior to founding Diego Pellicer, Jamen worked for Microsoft from 2003 to 2009 as Corporate Strategy Manager, where he focused on the creation and development of new categories of software products and online services. Preceding his Microsoft career he headed Shively International Inc., which built and operated both cybercafés and educational computer centers in Mexico. Just prior to founding Diego Pellicer Inc., Jamen founded and headed the online marketplace for the specialty food industry, Findood, winning first place in the Northwest Entrepreneur Network's First Look Forum Competition for the top new startup in 2010. Jamen completed his undergraduate work at U.C. Berkeley in Civil Engineering, and did graduate work at M.I.T. and U.C. Berkeley in Civil Engineering and Materials Science. He is a Fellow of the National Science Foundation.

Mr. Duffield added, "We are grateful for the years of service Mr. Rzepnicki provided to myself and to Plandaí over the past decade. He was one of the first to grasp the vision of the company and has been an unflagging ally over the years. As he focuses on his family and other business opportunities, we extend our sincerest thanks."

About Plandaí Biotechnology, Inc.

Plandaí Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandaí Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing its patented Phytofare(TM) extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.

Contact:

Andrew Beyer

Phone: [phone]

Email: investor@Plandaíbiotech.com

[webmimi]

Beobachte diese Aktie seit einiger Zeit. Die Berufung des Marketing-Experten Jamen Shively in den Aufsichtsrat von Plandai Biotechnology (PLPL) scheint ein Glücksgriff zu sein. Seine Ideen zeigen bereits erste Wirkungen und werden in den unterschiedlichsten US-Medien stark beachtet. In einem Interview bezeichnete sich der 40 jährige Manager jedoch selbst als "Pot Virgin" (Marihuana-Jungfrau)
Mit der neuen Cannabis-Edelmarke DIEGO PELLICER hat er große Pläne.
Shively kündigt an, das eine ganz besondere Sorte Cannabis von DIEGO PELLICER bald für 50,--$ pro Gramm angeboten werden wird. In den Vereinigten Staaten sollen, ähnlich wie nach dem STARBUCKS-Prinzip, hunderte von Filialen entstehen in denen anspruchsvolle Kunden u.a. das Luxus-Marihuana kaufen können.
Wie er selbst auf diese Idee kam (Marihuana spielte bei der Konzeption offensichtlich eine entscheidende Rolle ) und welches Potential er in diesem Milliarden-Dollar-Markt sieht kann in dem folgenden Artikel nachgelesen werden:

Quelle: http://www.vice.com/en_ca/read/the-40-year-old-pot-virgin

THE 40-YEAR-OLD POT VIRGIN
THE FORMER MICROSOFT EXECUTIVE WHO WANTS TO BUILD AMERICA'S FIRST NATIONAL MARIJUANA BRAND IS MOST DEFINITELY HIGH ON HIS OWN SUPPLY.

Jamen Shively only started smoking herb a-year-and a-half ago, but he's been making up for lost time ever since. Now an aspiring marijuana mogul, as well as a dedicated cannabis connoisseur, the 45-year-old former Microsoft executive even credits the very conception of his latest high-profile start-up venture to the enlightening influence of some top grade ganja. Specifically, a powerful sativa strain he broke out at an exploratory business meeting last November, just days after Washington state voters overwhelmingly approved pot legalization.

“I pulled out my stash, the dankest of the dank,” he recalls of that fateful occasion. “We fired up, and the concepts we generated were just incredible. Off the charts. Until the idea started to flow into creating a global juggernaut in what's going to be a trillion dollar market. We brainstormed so many different aspects of it, including the supply chain, financing, geopolitics, lobbying, genetics, even greenhouses. And it quickly became clear that we were sitting on an absolute gold mine.”

An evangelical admirer of the business book The 22 Immutable Laws of Marketing, Shively firmly believes it's better to be first to mind, than first to market. So before legalization even had a chance to take root, he began telling the press he was creating America's seminal national marijuana brand, and that his fledgling new enterprise would soon employ 10,000 people, while “minting more millionaires than Microsoft.”

“It actually becomes a virtuous cycle,” he explains to me over the phone, “the more outrageous claims I make—true claims—the more mindshare I get, and the bigger platform I have to discuss my plans. After all, what weed company is everybody talking about these days? The one run by an ex-Microsoft crackpot whose making all these outrageous claims.”

So let's take a closer look at just three claims Shively's made while promoting the Diego Pellicer brand, which he named after his great-grandfather, a 19th century hemp farmer.

“Diego Pellicer cannabis will retail for $50 per gram.”

This is like Shively saying he wants to create the Starbucks of marijuana (which he actually has said), only his national coffee chain charges about three times as much as the country's most expensive boutique roasters. When I ask if this tremendous mark-up will be attributable to some kind of high-end shopping experience, he says no way.

“Look, dude. This isn't taking a Big Mac and wrapping it in gold foil. We're talking about value based on the inherent quality of the cannabis itself. Because when I get high, I don't want it to be a so-so high. I want an experience that's going to last several hours... We live in a country where even middle class people won't settle for anything less than the best that they can get. And what's considered top quality in the available marijuana market is nothing compared to what we're creating.”

To which, all I can say is: I really look forward to sampling some cannabis that's three times better than the best I've ever had. (And Jamen, I'll in be in Seattle mid-September.)

“Marijuana will be legal, on a federal level, in all 50 states, in two years, tops.”

I first heard Shively make this prediction during an appearance on Huffington Post Live. He even promised the show's incredulous host that if proven wrong, “I will fly you [to Seattle] first class and put you up in my home. And we will get stoned. And you will enjoy it.”

Honestly, I'm struggling for a metaphor to properly explain how unlikely it is that his prediction will come true. How about this: If President Obama held a press conference first thing tomorrow morning, and wore a weed leaf button on his lapel instead of the American flag, while introducing Willie Nelson as the new head of the DEA, I'd still have 50-state pot legalization by June 2015 as an 18-1 underdog.

“We're not going to appeal to pot smokers. Our price is too high. Which makes our target market the law abiding citizens who will be first time users.”

This particular statement only ventures into the realm of the truly absurd when coupled with the companion claim that Diego Pellicer will be the largest distributor of cannabis nationwide, by securing a 40 percent market share of both recreational and medicinal marijuana sales in every state where it's legal. All by catering to high-end customers who've never smoked pot before in their lives, but have shitloads of cash to spend on it.

Now, I'm no expert on how demographic market research is supposed to work, but it sounds to me like Jamen Shively identified his ideal customer by simply looking in the mirror. Also, I sort of doubt Starbucks built their empire by focusing on first-time coffee drinkers.

The Mexican Connection

Most recently, in search of mind share, Shively held a joint press conference with former Mexican president Vicente Fox, who eloquently expressed his hope that marijuana legalization in the United States will help diminish the prohibition-fueled violence of the international drug cartels. Though Fox has no direct stake in Diego Pellicer or any other aspect of the cannabis industry, his high profile appearance before the press only fueled speculation that the brand might eventually look to import its product from south of the border.

“The whole topic of trade with Mexico got so far overblown it's kind of funny,” Shively says now that the smoke's cleared. “My whole point from the beginning was simply that we've got this big, hemispheric problem that may require a big, hemispheric solution. So we need to keep an open mind about things we might otherwise have a knee jerk reaction against.”

An interesting and even worthwhile thought experiment, no doubt. But perhaps one best kept to a smoky back room until the Feds finally call off their War on Weed.

“He's waiving a red flag at a bull,” UCLA Professor of Public Policy Mark A. R. Kleiman responds when I ask if Shively's plans might be seen as provocative by the US Department of Justice. Colloquially known as Washington's “pot czar,” Kleiman advises the state's Liquor Control Board on how to best implement the will of the people when it comes to recreational marijuana cultivation and sales, including by creating a system that adequately addresses the federal government's frequently voiced interest in preventing the rise of large-scale, multi-state marijuana enterprises.

“So going on TV to announce the creation of your large-scale, multi-state marijuana enterprise is certainly not helpful to the cause,” he says. “Nor is it consistent with any sane business strategy. The people entering this industry will be in a very equivocal position, and I suggest they keep their heads down. Not hold a press conference with Vicente Fox.”

After stressing that he's speaking with me not as an official of the state of Washington, but strictly in his role as an academic, a blogger, and an “all around nice guy who's single and looking,” the so-called pot czar wraps our call up by saying some less than nice things about the Diego Pellicer business model .

“The only thing I can imagine is that the goal is not to sell cannabis, but to sell stock,” Kleiman speculates. “I don't have any evidence, but that would make perfect sense. But even if this is a stock promotion, somebody's either crazy or stupid. Because this guy sounds like he'd sell you the Brooklyn Bridge, while taking the Verrazano as a trade-in.”

No Risk, High Reward

Perhaps the central selling point Shively's been using to attract potential investors is that his brand offers a “risk mitigated” way to get in on the ground floor of the sure to be lucrative marijuana production and distribution market without running afoul of the authorities.

“We've taken jail out of the equation,” he says. When I ask how that's possible, given federal law, Shively describes spending a ton of money in legal fees to come up with a proprietary “deal structure” that allows him to acquire medical marijuana dispensaries and recreational pot stores across the country without creating any criminal liability.

“When it's sufficiently legal to own them outright, we will. Until then, there's a whole different way we're going to operate.”

Diego Pellicer's first such acquisition was a Seattle medical marijuana access point called the North West Patient's Resource Center that maintains a stellar reputation within the industry and among lawmakers in Washington State. CEO John Davis has been a dedicated drug law reform advocate for decades. In 2008, he shared NORML's Cannabis Activist of the Year award for his role in helping to organize Seattle Hempfest, and he currently serves as Executive Director of the Coalition for Cannabis Standards and Ethics.

When I ask about his relationship with Jamen Shively, he says they're “married,” in the business sense, just three months after meeting for the first time.

“We each had what the other needed,” Davis explains. “I know the law, policy, procedures, the political landscape, and how to properly bring to market this particular product. While Jamen can access the financing I need to build infrastructure.”

Meanwhile, Shively says he's already looking to acquire additional retail outlets in Colorado and California, as soon as he completes an ongoing $10 million round of fundraising. The head of Diego Pellicer expects absolutely no problem reaching that initial eight-figure goal, though the current state of his coffers remains confidential, right alongside the risk mitigating details of his proprietary deal structure.

Ultimately, he's looking to raise $100 million to fully fund the company. Or perhaps to buy 200,000 grams of whatever he's been smoking.

David Bienenstock is the author of Legalized It!

Quelle: http://www.vice.com/en_ca/read/the-40-year-old-pot-virgin

[Popeye82]

ich habe die Aktie nicht.

Plandai Biotechnology, Inc. Announces Commencement of Human Bioavailability Study - Apr 14, 2014
www.stockhouse.com/news/press-releases/2014/04/14/plandai-bi…

"Planda Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced that it has received approval from the Ethics Committee at North West University in Potchefstroom, South Africa to commence a human clinical trial to test the oral bioavailability of its Phytofare Catechin Complex.

Phytofare is the trade name for live plant material extracts that have undergone the Company's proprietary hydrodynamic sheering process to rearrange the isomeric configuration of the molecules into a format biocompatible with human tissues.

The study will compare the oral bioavailability -- meaning the level of catechin absorption into the blood stream -- of Phytofare compared with green tea extracts that have not been processed as well as Phytofare that has subsequently been further entrapped in Pheroid. The Company anticipates that the trial will demonstrate that Phytofare and Phytofare entrapped in Pheroid have materially significant superior bioavailability, which should provide the ability to deliver a clinical level of plant nutrients as relatively low dosages. Planda believes that this will unlock the health potential of not only green tea but also other phytonutrients which suffer from low natural bioavailability.

According to the timeline provided by the University, the recruitment of the participants is scheduled to start on the 14th of April. The start date of the first leg, where the bioavailability of the comparator will be determined, is scheduled for the 11th of May. Final results from all three legs of the trial should be available in July 2014. North West University, located in Potchefstroom, South Africa, is considered one of the finest research facilities on the continent.

Planda Chairman and Chief Executive Officer Roger Duffield commented, "While we have exhaustively tested our Phytofare in several applications, including the recently concluded topical anti-aging study, the final piece for us is human bioavailability. Many phytonutrients exhibit tremendous potential in the lab for treating a host of medical and health conditions, but low oral absorption renders them ineffective when taken from the lab and into real world applications. At Planda, we believe that nature has provided us with most of what we need to combat everything from obesity to cancer to Alzheimer's -- we just need to improve our bodies' ability to process these nutrients. Phytofare will hopefully achieve that very thing."

Planda's first product to market will be Phytofare Catechin Complex, which includes the entire catechin profile derived from live green tea that is grown and processed on the Company's 8,000 acre Senteeko estate in South Africa. Later in 2014, and pending the results of a human clinical trial for treating cold and flu symptoms, the Company will begin producing Phytofare Limonoid Glycoside Complex, which contains citrus bioflavonoids.


About Planda Biotechnology, Inc.

Planda Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Planda Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing its patented Phytofare extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.


Safe Harbor Statement

The information provided may contain forward-looking statements and involve risks and uncertainties. Results, events and performances could vary from those contemplated. These statements involve risks and uncertainties which may cause actual results, expressed or implied, to differ from predicted outcomes. Risks and uncertainties include product demand, market competition, and Planda's ability to meet current or future plans. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Planda is not obliged to publicly release revisions to any forward-looking statement, to reflect events or circumstances afterward, or to disclose unanticipated occurrences, except as required under applicable laws.


Contact:

Andrew Beyer
Phone: [phone]
Email: [e-mail]

SOURCE: Plandai Biotechnology, Inc. "

[corecidex]

es geht wieder los...